Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Merger or Acquisition (February 2025)
11 slides from Novonesis A/s Class B's merger presentation, Feb 11, 2025
Slide 1: Acquisition of dsm-firmenich's share of the Feed Enzyme Alliance
Acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance February 11, 2025
Slide 2: Forward-looking statement
Forward-looking statement Disclaimer This announcement includes forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of the combined group and all of which are based on the combined group's current belief
Slide 3: Legacy Feed Enzyme Alliance has delivered sustainable value to the animal protein and feed industries
Legacy Feed Enzyme Alliance has delivered sustainable value to the animal protein and feed industries • Most complete and innovative feed and gut health enzyme portfolio built over >25 years • Clear industry enzyme-innovator over decades supported by leading scientific insights and development capab
Slide 4: New setup unlocks the full value of Novonesis' animal biosolutions
New setup unlocks the full value of Novonesis’ animal biosolutions Customers Old setup: Lacking full commercial access • Leading R&D, application and production of both enzymes and probiotics Enzymes dsm-firmenich Integrators R&D • Best-in-class enzymes and probiotics without ability to go to market
Slide 5: Direct customer access enables accelerated growth and innovation with reduced complexity
Direct customer access enables accelerated growth and innovation with reduced complexity Driving the complete value Leading position in Animal Attractive growth profile, chain biosolutions further enhanced by revenue synergies • Increased ability to directly • One consolidated go-to market • Acceler
Slide 6: Strategically aligned to unlock deeper customer relationships in a core business
Strategically aligned to unlock deeper customer relationships in a core business with accelerating growth potential Markets and solutions New Core Adjacencies Explorative Explorative growth Adjacencies opportunities Biggest contributor Biggest contributor Foundation for new Applications and & upsell
Slide 7: Strong financial profile with attractive growth and profitability
Strong financial profile with attractive growth and profitability Incremental contribution (12 months, EUR) to Novonesis Key Highlights Close to 3% ✓ Acquired growth contribution in year 1 Revenue ✓ Low-single-digit accretion to Novonesis’ animal biosolutions Growth accretion growth above mid-single
Slide 8: Transaction overview
Transaction overview • EUR 1.5 bn all cash purchase price for dsm-firmenich’s share of the Feed Enzyme Alliance • 100% debt financed (fully committed) • The expected strong cash generation will allow for deleveraging to the current target range of 1.3-1.7x NIBD/EBITDA within the next 2 years • No im
Slide 9: Summary
Summary • Driving the complete value chain • Leading position in Animal biosolutions • Attractive growth potential and strong earnings profile 9
Slide 10: novonesis
novonesis
Slide 11: Complete and synergistic portfolio of enzymes and probiotics in an attractive and growing animal biosolution market
Complete and synergistic portfolio of enzymes and probiotics in an attractive and growing animal biosolution market Products Benefits & species ENZYMES Phytases increase the availability of naturally • Maximize feed utilization occurring phosphorus in animal diets to • Optimize feed costs maximize a